{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:01:43Z","timestamp":1784584903445,"version":"3.55.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01403-2","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:22:12Z","timestamp":1784535732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of Troponins in CardioOncology"],"prefix":"10.1007","volume":"27","author":[{"given":"Jakub","family":"Homotnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"M\u0119drek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Rolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Zaborowska-Szmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-1943","authenticated-orcid":false,"given":"Sebastian","family":"Szmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"1403_CR1","doi-asserted-by":"publisher","unstructured":"Lv P, Zhang P, Dai Y, Ge J. Understanding the circulating forms of cardiac troponin: insights for clinical practice. Clin Chem Lab Med. 2025;63(9):1667\u20131681. https:\/\/doi.org\/10.1515\/cclm-2024-1236. PMID: 40440078.","DOI":"10.1515\/cclm-2024-1236"},{"issue":"6","key":"1403_CR2","doi-asserted-by":"publisher","first-page":"101263","DOI":"10.1016\/j.gendis.2024.101263","volume":"11","author":"R Ragusa","year":"2024","unstructured":"Ragusa R, Caselli C. Focus on cardiac troponin complex: From gene expression to cardiomyopathy. Genes Dis. 2024;11(6):101263. https:\/\/doi.org\/10.1016\/j.gendis.2024.101263. PMID: 39211905; PMCID: PMC11357864.","journal-title":"Genes Dis"},{"issue":"6","key":"1403_CR3","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.3390\/ijms25063117","volume":"25","author":"EA Arifulin","year":"2024","unstructured":"Arifulin EA, Sheval EV. Non-Canonical Localization of Cardiac Troponins: Expanding Functions or Causing Pathologies? Int J Mol Sci. 2024;25(6):3117. https:\/\/doi.org\/10.3390\/ijms25063117. PMID: 38542091; PMCID: PMC10970582.","journal-title":"Int J Mol Sci"},{"key":"1403_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120344","volume":"574","author":"Y Gao","year":"2025","unstructured":"Gao Y, Wang D, Mu D, Ma Y, Li Y, Qiu L, et al. Cardiac troponin. Clin Chim Acta. 2025;574:120344. https:\/\/doi.org\/10.1016\/j.cca.2025.120344.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"1403_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/09246479241302586","volume":"36","author":"Y Liu","year":"2025","unstructured":"Liu Y, Liu H. Prediction of chemotherapy-mediated cardiotoxicity in patients with cancer by cardiac troponin I: A systematic review and meta-analysis. Int J Risk Saf Med. 2025;36(1):26\u201348. Epub 2024 Nov 24. PMID: 39973426.","journal-title":"Int J Risk Saf Med"},{"issue":"2","key":"1403_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.1631","volume":"22","author":"L Michel","year":"2020","unstructured":"Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22(2):350\u201361. https:\/\/doi.org\/10.1002\/ejhf.1631.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1403_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11897-024-00681-x","volume":"21","author":"SW Romann","year":"2024","unstructured":"Romann SW, Giannitsis E, Frey N, Lehmann LH. Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications. Curr Heart Fail Rep. 2024;21(6):505\u201314. https:\/\/doi.org\/10.1007\/s11897-024-00681-x. Epub 2024 Sep 10. PMID: 39254897; PMCID: PMC11511716.","journal-title":"Curr Heart Fail Rep"},{"key":"1403_CR8","doi-asserted-by":"publisher","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244. Erratum in: Eur Heart J. 2023;44(18):1621. doi: 10.1093\/eurheartj\/ehad196. PMID: 36017568.","DOI":"10.1093\/eurheartj\/ehac244"},{"issue":"5","key":"1403_CR9","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1002\/ehf2.13515","volume":"8","author":"D Finke","year":"2021","unstructured":"Finke D, Romann SW, Heckmann MB, Hund H, Bougatf N, Kantharajah A, Katus HA, M\u00fcller OJ, Frey N, Giannitsis E, Lehmann LH. High-sensitivity cardiac troponin T determines all-cause mortality in cancer patients: a single-centre cohort study. ESC Heart Fail. 2021;8(5):3709\u201319. Epub 2021 Aug 15. PMID: 34396713; PMCID: PMC8497378.","journal-title":"ESC Heart Fail"},{"key":"1403_CR10","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Send\u00f3n J, \u00c1lvarez-Ortega C, Zamora Au\u00f1on P, Bu\u00f1o Soto A, Lyon AR, Farmakis D, Cardinale D, Canales Albendea M, Feliu Batlle J, Rodr\u00edguez Rodr\u00edguez I, Rodr\u00edguez Fraga O, Albaladejo A, Mediavilla G, Gonz\u00e1lez-Juanatey JR, Mart\u00ednez Monzonis A, G\u00f3mez, Prieto P, Gonz\u00e1lez-Costello J. Serrano Antol\u00edn JM, Cadenas Chamorro R, L\u00f3pez Fern\u00e1ndez T. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720\u20131729. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa006. PMID: 32016393.","DOI":"10.1093\/eurheartj\/ehaa006"},{"issue":"2","key":"1403_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00392-021-01894-z","volume":"111","author":"LH Lehmann","year":"2022","unstructured":"Lehmann LH, Stein F, J\u00e4ger D, Frey N. The Heidelberg cardio-oncology unit (COUNT)-a possible blueprint for improved care of cardio-oncological patients. Clin Res Cardiol. 2022;111(2):227\u20139. https:\/\/doi.org\/10.1007\/s00392-021-01894-z. Epub 2021 Jun 28. PMID: 34181066; PMCID: PMC8817047.","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"1403_CR12","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil R, Mueller C, \u010celutkien\u0117 J, Henriksen PA, Lenihan D, Dent S, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22(11):1966\u201383. https:\/\/doi.org\/10.1002\/ejhf.2017.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"1403_CR13","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"J \u010celutkien\u0117","year":"2020","unstructured":"\u010celutkien\u0117 J, Pudil R, L\u00f3pez-Fern\u00e1ndez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22(9):1504\u201324. https:\/\/doi.org\/10.1002\/ejhf.1957.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1403_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","volume":"148","author":"LH Lehmann","year":"2023","unstructured":"Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, et al. Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation. 2023;148(6):473\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.062405.","journal-title":"Circulation"},{"issue":"2","key":"1403_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ajh.27177","volume":"99","author":"MA Gertz","year":"2024","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment. Am J Hematol. 2024;99(2):309\u201324. https:\/\/doi.org\/10.1002\/ajh.27177.","journal-title":"Am J Hematol"},{"issue":"6","key":"1403_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jamacardio.2024.0459","volume":"9","author":"S Saadatagah","year":"2024","unstructured":"Saadatagah S, Naderian M, Uddin M, Dikilitas O, Niroula A, Schuermans A, Selvin E, Hoogeveen RC, Matsushita K, Nambi V, Yu B, Chen LY, Bick AG, Ebert BL, Honigberg MC, Li N, Shah A, Natarajan P, Kullo IJ, Ballantyne CM. Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1. JAMA Cardiol. 2024;9(6):497\u2013506. https:\/\/doi.org\/10.1001\/jamacardio.2024.0459. PMID: 38598228; PMCID: PMC11007653.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"1403_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","volume":"9","author":"P Thavendiranathan","year":"2023","unstructured":"Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, Huang F, Shalmon T, Thorpe KE, Pezo RC, Prica A, Maze D, Abdel-Qadir H, Connelly KA, Chan J, Billia F, Power C, Hanneman K, Wintersperger BJ, Brezden-Masley C, Amir E. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother. 2023;9(6):515\u201325. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad031. PMID: 37120736; PMCID: PMC10509566.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"4","key":"1403_CR18","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jaccao.2024.06.002","volume":"6","author":"I Nardi-Agmon","year":"2024","unstructured":"Nardi-Agmon I, Di Meo A, Lam L, Kyle C, Abdel-Qadir H, Amir E, Thavendiranathan P. Circulating Macrotroponin Complexes and Their Impact on Cardiac Troponin Measurements: Potential Implications for Cardio-Oncology. JACC CardioOncol. 2024;6(4):608\u201311. PMID: 39239330; PMCID: PMC11372023.","journal-title":"JACC CardioOncol"},{"issue":"3","key":"1403_CR19","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/life14030400","volume":"14","author":"NG Kounis","year":"2024","unstructured":"Kounis NG, Hung MY, de Gregorio C, Mplani V, Gogos C, Assimakopoulos SF, Plotas P, Dousdampanis P, Kouni SN, Maria A, Tsigkas G, Koniari I. Cardio-Oncoimmunology: Cardiac Toxicity, Cardiovascular Hypersensitivity, and Kounis Syndrome. Life (Basel). 2024;14(3):400. https:\/\/doi.org\/10.3390\/life14030400. PMID: 38541723; PMCID: PMC10971934.","journal-title":"Life (Basel)"},{"issue":"2","key":"1403_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40119-020-00187-2","volume":"9","author":"A Kearney","year":"2020","unstructured":"Kearney A, Corry N, Menown IBA. Massive Left Atrial Myxoma Presenting With Troponin-Positive Chest Pain. Cardiol Ther. 2020;9(2):577\u201380. https:\/\/doi.org\/10.1007\/s40119-020-00187-2. Epub 2020 Jul 27. PMID: 32720069; PMCID: PMC7584706.","journal-title":"Cardiol Ther"},{"key":"1403_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110479","volume":"200","author":"JC Beukema","year":"2024","unstructured":"Beukema JC, Haveman JW, Langendijk JA, Oldehinkel E, van den Bergh ACM, de Haan JJ, et al. Blood biomarkers for cardiac damage during and after radiotherapy for esophageal cancer: a prospective cohort study. Radiother Oncol. 2024;200:110479. https:\/\/doi.org\/10.1016\/j.radonc.2024.110479.","journal-title":"Radiother Oncol"},{"key":"1403_CR22","doi-asserted-by":"publisher","unstructured":"Al-Hawwas M, Tsitlakidou D, Gupta N, Iliescu C, Cilingiroglu M, Marmagkiolis K. Acute Coronary Syndrome Management in Cancer Patients. Curr Oncol Rep. 2018;20(10):78. https:\/\/doi.org\/10.1007\/s11912-018-0724-8. PMID: 30132257.","DOI":"10.1007\/s11912-018-0724-8"},{"issue":"12","key":"1403_CR23","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s00392-024-02438-x","volume":"113","author":"I Nardi Agmon","year":"2024","unstructured":"Nardi Agmon I, Rahat O, Beigel R, Ovdat T, Habib M, Tzuman O, Bushari LI, Kornowski R, Orvin K. Short- and long-term outcomes of patients with active cancer presenting with an acute coronary syndrome. Clin Res Cardiol. 2024;113(12):1707\u201316. https:\/\/doi.org\/10.1007\/s00392-024-02438-x. Epub 2024 Mar 20. PMID: 38507056.","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"1403_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jaccao.2024.03.005","volume":"6","author":"M Totzeck","year":"2024","unstructured":"Totzeck M, Rassaf T. Natriuretic Peptides and Troponins: Sufficient Monitoring of Cancer Survivors? JACC CardioOncol. 2024;6(2):248\u201350. https:\/\/doi.org\/10.1016\/j.jaccao.2024.03.005. PMID: 38774019; PMCID: PMC11103026.","journal-title":"JACC CardioOncol"},{"key":"1403_CR25","first-page":"101522","volume":"55","author":"M Cronin","year":"2024","unstructured":"Cronin M, Neiroukh D, Lowery A, Wijns W, Kerin M, Keane M, Blazkova S, Soliman O. Proposed framework regarding management of patients with breast cancer and anti-cancer treatment-related elevation in cardiac troponin. Int J Cardiol Heart Vasc. 2024;55:101522. PMID: 39498346; PMCID: PMC11532442.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"11","key":"1403_CR26","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, L\u00f3pez-Fern\u00e1ndez T, Plummer C, Lenihan D. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945\u201360. https:\/\/doi.org\/10.1002\/ejhf.1920. Epub 2020 Aug 6. PMID: 32463967; PMCID: PMC8019326.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1403_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40959-025-00358-x","volume":"11","author":"LB Leypoldt","year":"2025","unstructured":"Leypoldt LB, Guo L, Besemer B, H\u00e4nel M, Raab MS, Mann C, Michel CS, Reinhardt HC, Blau IW, G\u00f6rner M, Ko YD, de Wit M, Salwender H, Scheid C, Graeven U, Peceny R, Staib P, Dieing A, Goldschmidt H, Bokemeyer C, Zeller T, Westermann D, Weisel KC, Twerenbold R, Beitzen-Heineke A. Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial. Cardiooncology. 2025;11(1):63. https:\/\/doi.org\/10.1186\/s40959-025-00358-x. PMID: 40611354; PMCID: PMC12224601.","journal-title":"Cardiooncology"},{"issue":"1","key":"1403_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ehf2.14587","volume":"11","author":"SW Romann","year":"2024","unstructured":"Romann SW, Finke D, Heckmann MB, Hund H, Giannitsis E, Katus HA, et al. Cardiological parameters predict mortality and cardiotoxicity in oncological patients. ESC Heart Fail. 2024;11(1):366\u201377. https:\/\/doi.org\/10.1002\/ehf2.14587.","journal-title":"ESC Heart Fail"},{"issue":"8","key":"1403_CR29","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1007\/s00277-025-06523-7","volume":"104","author":"DR Lazar","year":"2025","unstructured":"Lazar DR, Maniu D, Lazar FL, Blag C, Bota M, Zdrenghea M, Cainap S. Exploring the baseline cardiac function and its correlation with risk stratification in children diagnosed with acute lymphoblastic leukemia. Ann Hematol. 2025;104(8):4157\u201364. https:\/\/doi.org\/10.1007\/s00277-025-06523-7. Epub 2025 Jul 30. PMID: 40736552; PMCID: PMC12432049.","journal-title":"Ann Hematol"},{"issue":"1","key":"1403_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40959-023-00174-1","volume":"9","author":"M Dean","year":"2023","unstructured":"Dean M, Kim MJ, Dimauro S, Tannenbaum S, Graham G, Liang BT, Kim AS. Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy - a prospective analysis. Cardiooncology. 2023;9(1):23. https:\/\/doi.org\/10.1186\/s40959-023-00174-1. PMID: 37106424; PMCID: PMC10133897.","journal-title":"Cardiooncology"},{"issue":"21","key":"1403_CR31","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","volume":"148","author":"PA Henriksen","year":"2023","unstructured":"Henriksen PA, Hall P, MacPherson IR, Joshi SS, Singh T, Maclean M, Lewis S, Rodriguez A, Fletcher A, Everett RJ, Stavert H, Broom A, Eddie L, Primrose L, McVicars H, McKay P, Borley A, Rowntree C, Lord S, Collins G, Radford J, Guppy A, Williams MC, Japp A, Payne JR, Newby DE, Mills NL, Oikonomidou O, Lang NN. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. Circulation. 2023;148(21):1680\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064274. Epub 2023 Sep 25. PMID: 37746692; PMCID: PMC10655910.","journal-title":"Circulation"},{"key":"1403_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.biopha.2018.08.035","volume":"107","author":"R Sim\u00f5es","year":"2018","unstructured":"Sim\u00f5es R, Silva LM, Cruz ALVM, Fraga VG, de Paula Sabino A, Gomes KB. Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy: a narrative review. Biomed Pharmacother. 2018;107:989\u201396. https:\/\/doi.org\/10.1016\/j.biopha.2018.08.035.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"1403_CR33","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/life12081183","volume":"12","author":"V Sorodoc","year":"2022","unstructured":"Sorodoc V, Sirbu O, Lionte C, Haliga RE, Stoica A, Ceasovschih A, Petris OR, Constantin M, Costache II, Petris AO, Morariu PC, Sorodoc L. The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity. Life (Basel). 2022;12(8):1183. https:\/\/doi.org\/10.3390\/life12081183. PMID: 36013362; PMCID: PMC9410123.","journal-title":"Life (Basel)"},{"issue":"5","key":"1403_CR34","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1253\/circj.CJ-24-0065","volume":"88","author":"K Inoue","year":"2024","unstructured":"Inoue K, Machino-Ohtsuka T, Nakazawa Y, Iida N, Sasamura R, Bando H, Chiba S, Tasaka N, Ishizu T, Murakoshi N, Xu D, Sekine I, Tajiri K. Early Detection and Prediction of Anthracycline-Induced Cardiotoxicity - A Prospective Cohort Study. Circ J. 2024;88(5):751\u20139. https:\/\/doi.org\/10.1253\/circj.CJ-24-0065. Epub 2024 Mar 8. PMID: 38462534.","journal-title":"Circ J"},{"issue":"1","key":"1403_CR35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40959-025-00386-7","volume":"11","author":"HA Saeed","year":"2025","unstructured":"Saeed HA, Mohammed Ali NA, Othman RT. Anthracycline- and HER2-induced cardiotoxicity: mechanisms, current strategies, and the emerging role of dapagliflozin as a targeted cardioprotective agent. Cardiooncology. 2025;11(1):100. https:\/\/doi.org\/10.1186\/s40959-025-00386-7. PMID: 41189010; PMCID: PMC12584439.","journal-title":"Cardiooncology"},{"issue":"6","key":"1403_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.14744\/AnatolJCardiol.2023.2825","volume":"27","author":"S Ulusan","year":"2023","unstructured":"Ulusan S, G\u00fclle K, Peynirci A, Sevimli M, Karaibrahimoglu A, Kuyumcu MS. Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity. Anatol J Cardiol. 2023;27(6):339\u201347. PMID: 37257007; PMCID: PMC10250773.","journal-title":"Anatol J Cardiol"},{"issue":"7","key":"1403_CR37","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1161\/CIRCULATIONAHA.122.062814","volume":"147","author":"SJ Foulkes","year":"2023","unstructured":"Foulkes SJ, Howden EJ, Haykowsky MJ, Antill Y, Salim A, Nightingale SS, et al. Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the BREXIT study. Circulation. 2023;147(7):532\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062814.","journal-title":"Circulation"},{"issue":"6","key":"1403_CR38","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.2023.11887","volume":"330","author":"TG Neilan","year":"2023","unstructured":"Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, Smith A, Heemelaar JC, Brahmbhatt P, Ho JS, Sama S, Svoboda J, Neuberg DS, Abramson JS, Hochberg EP, Barnes JA, Armand P, Jacobsen ED, Jacobson CA, Kim AI, Soumerai JD, Han Y, Friedman RS, Lacasce AS, Ky B, Landsburg D, Nasta S, Kwong RY, Jerosch-Herold M, Redd RA, Hua L, Januzzi JL, Asnani A, Mousavi N, Scherrer-Crosbie M. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA. 2023;330(6):528\u201336. https:\/\/doi.org\/10.1001\/jama.2023.11887. PMID: 37552303; PMCID: PMC10410476.","journal-title":"JAMA"},{"key":"1403_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejim.2024.04.007","volume":"126","author":"N Felix","year":"2024","unstructured":"Felix N, Nogueira PC, Silva IM, Costa TA, Campello CA, Stecca C, et al. Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: an updated meta-analysis of randomized controlled trials. Eur J Intern Med. 2024;126:43\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2024.04.007.","journal-title":"Eur J Intern Med"},{"issue":"2","key":"1403_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jaccao.2024.11.008","volume":"7","author":"V Juhasz","year":"2025","unstructured":"Juhasz V, Quinaglia T, Drobni ZD, Heemelaar JC, Neuberg DS, Han Y, Ky B, Kwong RY, Januzzi JL, Asnani A, Redd RA, Mousavi N, Jerosch-Herold M, Scherrer-Crosbie M, Neilan TG. Atorvastatin and Myocardial Extracellular Volume Expansion During Anthracycline-Based Chemotherapy. JACC CardioOncol. 2025;7(2):125\u201337. Epub 2025 Jan 28. PMID: 39967198; PMCID: PMC11866434.","journal-title":"JACC CardioOncol"},{"key":"1403_CR41","doi-asserted-by":"publisher","first-page":"1083462","DOI":"10.3389\/fimmu.2022.1083462","volume":"13","author":"F Li","year":"2022","unstructured":"Li F, Liu S. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer. Front Immunol. 2022;13:1083462. https:\/\/doi.org\/10.3389\/fimmu.2022.1083462. PMID: 36601109; PMCID: PMC9806173.","journal-title":"Front Immunol"},{"issue":"1","key":"1403_CR42","doi-asserted-by":"publisher","first-page":"e003171","DOI":"10.1136\/jitc-2021-003171","volume":"10","author":"A Musolino","year":"2022","unstructured":"Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram MD. Role of Fc\u03b3 receptors in HER2-targeted breast cancer therapy. J Immunother Cancer. 2022;10(1):e003171. https:\/\/doi.org\/10.1136\/jitc-2021-003171. PMID: 34992090; PMCID: PMC8739678.","journal-title":"J Immunother Cancer"},{"key":"1403_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2021.08.007","volume":"60","author":"P Mand\u00f3","year":"2021","unstructured":"Mand\u00f3 P, Rivero SG, Rizzo MM, Pinkasz M, Levy EM, Targeting ADCC. A different approach to HER2 breast cancer in the immunotherapy era. Breast. 2021;60:15\u201325. https:\/\/doi.org\/10.1016\/j.breast.2021.08.007. Epub 2021 Aug 19. PMID: 34454323; PMCID: PMC8399304.","journal-title":"Breast"},{"issue":"1","key":"1403_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/MS9.0000000000002753","volume":"87","author":"NA Ahmed","year":"2025","unstructured":"Ahmed NA, Redwan FN, Jahjah AS, Al-Shehabi ZA. Evaluating high-sensitivity cardiac troponin I for early detection of treatment-related cardiotoxicity in HER2-positive breast cancer patients. Ann Med Surg (Lond). 2025;87(1):93\u2013102. PMID: 40109639; PMCID: PMC11918789.","journal-title":"Ann Med Surg (Lond)"},{"issue":"8","key":"1403_CR45","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474\u2013502. https:\/\/doi.org\/10.1038\/s41569-020-0348-1. Epub 2020 Mar 30. PMID: 32231332; PMCID: PMC8782611.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"1403_CR46","doi-asserted-by":"publisher","first-page":"14312","DOI":"10.1038\/s41598-022-18342-1","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang Y, Meng W, Zhao W, Tong Z. Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer. Sci Rep. 2022;12(1):14312. https:\/\/doi.org\/10.1038\/s41598-022-18342-1. PMID: 35995984; PMCID: PMC9395410.","journal-title":"Sci Rep"},{"issue":"2","key":"1403_CR47","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/ehf2.13782","volume":"9","author":"B D\u00edaz-Ant\u00f3n","year":"2022","unstructured":"D\u00edaz-Ant\u00f3n B, Madurga R, Zorita B, Wasniewski S, Moreno-Arciniegas A, L\u00f3pez-Melgar B, Ram\u00edrez Merino N, Mart\u00edn-Asenjo R, Barrio P, Amado Esca\u00f1uela MG, Sol\u00eds J, Parra Jim\u00e9nez FJ, Ciruelos E, Castellano JM, Fern\u00e1ndez-Friera L. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters. ESC Heart Fail. 2022;9(2):1127\u201337. https:\/\/doi.org\/10.1002\/ehf2.13782. Epub 2022 Feb 2. PMID: 35106939; PMCID: PMC8934964.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"1403_CR48","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","volume":"9","author":"C Tomuleasa","year":"2024","unstructured":"Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, Kegyes D, Onaciu A, Gulei D, Ghiaur G, Einsele H, Croce CM. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct Target Ther. 2024;9(1):201. https:\/\/doi.org\/10.1038\/s41392-024-01899-w. PMID: 39138146; PMCID: PMC11323831.","journal-title":"Signal Transduct Target Ther"},{"key":"1403_CR49","doi-asserted-by":"publisher","first-page":"100195","DOI":"10.1016\/j.medidd.2024.100195","volume":"23","author":"R Kumar","year":"2024","unstructured":"Kumar R, Goel H, Solanki R, Rawat L, Tabasum S, Tanwar P, Pal S, Sabarwal A. Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy. Med Drug Discov. 2024;23:100195. https:\/\/doi.org\/10.1016\/j.medidd.2024.100195. Epub 2024 Jul 1. PMID: 39281823; PMCID: PMC11393807.","journal-title":"Med Drug Discov"},{"issue":"4","key":"1403_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","volume":"80","author":"N Ebrahimi","year":"2023","unstructured":"Ebrahimi N, Fardi E, Ghaderi H, Palizdar S, Khorram R, Vafadar R, Ghanaatian M, Rezaei-Tazangi F, Baziyar P, Ahmadi A, Hamblin MR, Aref AR. Receptor tyrosine kinase inhibitors in cancer. Cell Mol Life Sci. 2023;80(4):104. https:\/\/doi.org\/10.1007\/s00018-023-04729-4. PMID: 36947256; PMCID: PMC11073124.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1403_CR51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther. 2022;7(1):329. https:\/\/doi.org\/10.1038\/s41392-022-01168-8. PMID: 36115852; PMCID: PMC9482625.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"1403_CR52","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.3390\/ijms23073830","volume":"23","author":"FMC de Pinho Pessoa","year":"2022","unstructured":"de Pinho Pessoa FMC, Machado CB, da Silva EL, da Costa Pantoja L, Ribeiro RM, de Moraes MEA, de Moraes Filho MO, Montenegro RC, Khayat AS, Moreira-Nunes CA. Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution. Int J Mol Sci. 2022;23(7):3830. https:\/\/doi.org\/10.3390\/ijms23073830. PMID: 35409190; PMCID: PMC8998551.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"1403_CR53","doi-asserted-by":"publisher","first-page":"10008","DOI":"10.3390\/ijms251810008","volume":"25","author":"H Dickerson","year":"2024","unstructured":"Dickerson H, Diab A, Al Musaimi O. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects. Int J Mol Sci. 2024;25(18):10008. https:\/\/doi.org\/10.3390\/ijms251810008. PMID: 39337496; PMCID: PMC11432255.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1403_CR54","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12916-023-02838-2","volume":"21","author":"H Wang","year":"2023","unstructured":"Wang H, Wang Y, Li J, He Z, Boswell SA, Chung M, You F, Han S. Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes. BMC Med. 2023;21(1):147. https:\/\/doi.org\/10.1186\/s12916-023-02838-2. PMID: 37069550; PMCID: PMC10108821.","journal-title":"BMC Med"},{"key":"1403_CR55","doi-asserted-by":"publisher","first-page":"1593290","DOI":"10.3389\/fphar.2025.1593290","volume":"16","author":"M Yan","year":"2025","unstructured":"Yan M, Peng C, Lang X, Li Y, Zhang Y. Mechanisms of sorafenib-induced cardiotoxicity: ER stress induces upregulation of ATF3, leading to downregulation of NDUFS1 expression and mitochondrial dysfunction. Front Pharmacol. 2025;16:1593290. PMID: 40880646; PMCID: PMC12380775.","journal-title":"Front Pharmacol"},{"key":"1403_CR56","doi-asserted-by":"publisher","first-page":"1163137","DOI":"10.3389\/fmed.2023.1163137","volume":"10","author":"R Kaddoura","year":"2023","unstructured":"Kaddoura R, Dabdoob WA, Ahmed K, Yassin MA. A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia. Front Med (Lausanne). 2023;10:1163137. https:\/\/doi.org\/10.3389\/fmed.2023.1163137. PMID: 37358999; PMCID: PMC10286131.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"1403_CR57","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.hfc.2022.02.003","volume":"18","author":"SS Scott","year":"2022","unstructured":"Scott SS, Greenlee AN, Matzko A, Stein M, Naughton MT, Zaramo TZ, et al. Intracellular signaling pathways mediating tyrosine kinase inhibitor cardiotoxicity. Heart Fail Clin. 2022;18(3):425\u201342. https:\/\/doi.org\/10.1016\/j.hfc.2022.02.003.","journal-title":"Heart Fail Clin"},{"key":"1403_CR58","doi-asserted-by":"publisher","first-page":"1002438","DOI":"10.3389\/fcvm.2023.1002438","volume":"10","author":"Q Liu","year":"2023","unstructured":"Liu Q, Li S, Qiu Y, Zhang J, Rios FJ, Zou Z, Touyz RM. Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7. Front Cardiovasc Med. 2023;10:1002438. https:\/\/doi.org\/10.3389\/fcvm.2023.1002438. PMID: 36818331; PMCID: PMC9936099.","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"1403_CR59","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000505486","volume":"98","author":"G Novo","year":"2020","unstructured":"Novo G, Di Lisi D, Bronte E, Macaione F, Accurso V, Badalamenti G, Rinaldi G, Siragusa S, Novo S, Russo A. Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience. Oncology. 2020;98(7):445\u201351. Epub 2020 Apr 29. PMID: 32348984.","journal-title":"Oncology"},{"issue":"1","key":"1403_CR60","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3390\/biomedicines11010181","volume":"11","author":"B Franczyk","year":"2023","unstructured":"Franczyk B, Rysz J, \u0141awi\u0144ski J, Cia\u0142kowska-Rysz A, Gluba-Brz\u00f3zka A. Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma. Biomedicines. 2023;11(1):181. https:\/\/doi.org\/10.3390\/biomedicines11010181. PMID: 36672689; PMCID: PMC9855533.","journal-title":"Biomedicines"},{"issue":"1","key":"1403_CR61","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40959-022-00147-w","volume":"8","author":"MS Andres","year":"2022","unstructured":"Andres MS, Ramalingam S, Rosen SD, Baksi J, Khattar R, Kirichenko Y, Young K, Yousaf N, Okines A, Huddart R, Harrington K, Furness AJS, Turajlic S, Pickering L, Popat S, Larkin J, Lyon AR. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: Including myocarditis and the new entity of non inflammatory left ventricular dysfunction. Cardiooncology. 2022;8(1):21. https:\/\/doi.org\/10.1186\/s40959-022-00147-w. PMID: 36424659; PMCID: PMC9685864.","journal-title":"Cardiooncology"},{"issue":"7","key":"1403_CR62","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3390\/diagnostics13071243","volume":"13","author":"L Zotova","year":"2023","unstructured":"Zotova L. Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases. Diagnostics (Basel). 2023;13(7):1243. https:\/\/doi.org\/10.3390\/diagnostics13071243. PMID: 37046461; PMCID: PMC10093455.","journal-title":"Diagnostics (Basel)"},{"issue":"6","key":"1403_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002553","volume":"9","author":"I Puzanov","year":"2021","unstructured":"Puzanov I, Subramanian P, Yatsynovich YV, Jacobs DM, Chilbert MR, Sharma UC, et al. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer. 2021;9(6):e002553. https:\/\/doi.org\/10.1136\/jitc-2021-002553.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"1403_CR64","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.3390\/ijms25105490","volume":"25","author":"J Qiu","year":"2024","unstructured":"Qiu J, Cheng Z, Jiang Z, Gan L, Zhang Z, Xie Z. Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment. Int J Mol Sci. 2024;25(10):5490. https:\/\/doi.org\/10.3390\/ijms25105490. PMID: 38791528; PMCID: PMC11122264.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1403_CR65","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s11684-023-1025-7","volume":"17","author":"L Liao","year":"2023","unstructured":"Liao L, Xu H, Zhao Y, Zheng X. Metabolic interventions combined with CTLA-4 and PD-1\/PD-L1 blockade for the treatment of tumors: mechanisms and strategies. Front Med. 2023;17(5):805\u201322. https:\/\/doi.org\/10.1007\/s11684-023-1025-7.","journal-title":"Front Med"},{"issue":"Pt 3","key":"1403_CR66","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.semcancer.2020.12.001","volume":"86","author":"DY Lee","year":"2022","unstructured":"Lee DY, Im E, Yoon D, Lee YS, Kim GS, Kim D, et al. Pivotal role of PD-1\/PD-L1 immune checkpoints in immune escape and cancer progression: their interplay with platelets and FOXP3+ Tregs related molecules, clinical implications and combinational potential with phytochemicals. Semin Cancer Biol. 2022;86(Pt 3):1033\u201357. https:\/\/doi.org\/10.1016\/j.semcancer.2020.12.001.","journal-title":"Semin Cancer Biol"},{"key":"1403_CR67","doi-asserted-by":"publisher","first-page":"1688699","DOI":"10.3389\/fimmu.2025.1688699","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, He J, Ding G, Tang Y, Wang Q. Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. Front Immunol. 2025;16:1688699. https:\/\/doi.org\/10.3389\/fimmu.2025.1688699. PMID: 41112253; PMCID: PMC12531160.","journal-title":"Front Immunol"},{"issue":"5","key":"1403_CR68","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O\u2019Byrne K, Kulasinghe A. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044\u201360. https:\/\/doi.org\/10.3390\/curroncol29050247. PMID: 35621637; PMCID: PMC9139602.","journal-title":"Curr Oncol"},{"issue":"1","key":"1403_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40959-021-00114-x","volume":"7","author":"E Matzen","year":"2021","unstructured":"Matzen E, Bartels LE, L\u00f8gstrup B, Horsk\u00e6r S, Stilling C, Donskov F. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. Cardiooncology. 2021;7(1):27. https:\/\/doi.org\/10.1186\/s40959-021-00114-x. PMID: 34365980; PMCID: PMC8351114.","journal-title":"Cardiooncology"},{"issue":"11","key":"1403_CR70","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/ijc.34169","volume":"151","author":"R Cau","year":"2022","unstructured":"Cau R, Solinas C, De Silva P, Lambertini M, Agostinetto E, Scartozzi M, et al. Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis. Int J Cancer. 2022;151(11):1860\u201373. https:\/\/doi.org\/10.1002\/ijc.34169.","journal-title":"Int J Cancer"},{"key":"1403_CR71","doi-asserted-by":"publisher","unstructured":"Tamura Y, Tamura Y. Evaluating Troponin-Based Monitoring in Patients Undergoing Immune Checkpoint Inhibitor Therapy. JACC Adv. 2024;3(12):101374. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101374. PMID: 39583871; PMCID: PMC11584775.","DOI":"10.1016\/j.jacadv.2024.101374"},{"issue":"11","key":"1403_CR72","doi-asserted-by":"publisher","first-page":"100598","DOI":"10.1016\/j.apjon.2024.100598","volume":"11","author":"T Oyakawa","year":"2024","unstructured":"Oyakawa T, Muraoka N, Iida K, Fujita A, Yokoyama K, Ishikawa H, Murakami H. Relevance of surveillance manual for the early detection of immune checkpoint inhibitor-induced myocarditis: A case series. Asia Pac J Oncol Nurs. 2024;11(11):100598. PMID: 39582548; PMCID: PMC11582373.","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"6","key":"1403_CR73","doi-asserted-by":"publisher","first-page":"oyaf147","DOI":"10.1093\/oncolo\/oyaf147","volume":"30","author":"M Gvili Perelman","year":"2025","unstructured":"Gvili Perelman M, Brzezinski RY, Waissengrin B, Leshem Y, Raphael A, Perelman M, Weiss N, Tzuberi M, Stark M, Goldiner I, Khoury S, Havakuk O, Topilsky Y, Banai S, Asleh R, Wolf I, Laufer-Perl M. The predictive value of serial troponin measurements in patients treated with immune checkpoint inhibitors. Oncologist. 2025;30(6):oyaf147. https:\/\/doi.org\/10.1093\/oncolo\/oyaf147. PMID: 40579948; PMCID: PMC12205246.","journal-title":"Oncologist"},{"issue":"9","key":"1403_CR74","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.21037\/jtd-23-596","volume":"15","author":"Y He","year":"2023","unstructured":"He Y, Chen W, Cai J, Luo C, Zhou C, Wei L. PD-1 inhibitors-associated myocarditis in non-small cell lung cancer patients. J Thorac Dis. 2023;15(9):4606\u201319. https:\/\/doi.org\/10.21037\/jtd-23-596. Epub 2023 Aug 14. PMID: 37868865; PMCID: PMC10586979.","journal-title":"J Thorac Dis"},{"issue":"4","key":"1403_CR75","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/ph16040625","volume":"16","author":"D Delombaerde","year":"2023","unstructured":"Delombaerde D, De Sutter J, Croes L, Vervloet D, Moerman V, Van de Veire N, Willems AM, Wouters K, Peeters M, Prenen H, Vulsteke C. Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study. Pharmaceuticals (Basel). 2023;16(4):625. https:\/\/doi.org\/10.3390\/ph16040625. PMID: 37111382; PMCID: PMC10142365.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"1403_CR76","doi-asserted-by":"publisher","first-page":"101375","DOI":"10.1016\/j.jacadv.2024.101375","volume":"3","author":"PF van den Berg","year":"2024","unstructured":"van den Berg PF, Bracun V, Noordman M, van der Meer P, Shi C, Oosting SF, Aboumsallem JP, de Wit S, Meijers WC, Jalving M, van Kruchten M, de Boer RA. Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors: Data From a Prospective Study. JACC Adv. 2024;3(12):101375. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101375. PMID: 39583866; PMCID: PMC11584941.","journal-title":"JACC Adv"},{"issue":"5","key":"1403_CR77","doi-asserted-by":"publisher","first-page":"634","DOI":"10.21873\/cdp.10479","volume":"5","author":"Y Shibutani","year":"2025","unstructured":"Shibutani Y, Imaoka T, Suzuki A, Tajiri K. Asymptomatic Troponin Elevation and Early Mortality Following Immune Checkpoint Inhibitor Therapy in Patients Without Cardiac Adverse Events. Cancer Diagn Progn. 2025;5(5):634\u201341. https:\/\/doi.org\/10.21873\/cdp.10479. PMID: 40900883; PMCID: PMC12401031.","journal-title":"Cancer Diagn Progn"},{"issue":"7","key":"1403_CR78","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/ph17070965","volume":"17","author":"D Delombaerde","year":"2024","unstructured":"Delombaerde D, Vulsteke C, Van de Veire N, Vervloet D, Moerman V, Van Calster L, Willems AM, Croes L, Gremonprez F, De Meulenaere A, Elzo Kraemer X, Wouters K, Peeters M, Prenen H, De Sutter J. Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors. Pharmaceuticals (Basel). 2024;17(7):965. https:\/\/doi.org\/10.3390\/ph17070965. PMID: 39065813; PMCID: PMC11279915.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1403_CR79","doi-asserted-by":"publisher","first-page":"835510","DOI":"10.3389\/fphar.2022.835510","volume":"13","author":"H Dong","year":"2022","unstructured":"Dong H, Qi Y, Kong X, Wang Z, Fang Y, Wang J. PD-1\/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. Front Pharmacol. 2022;13:835510. https:\/\/doi.org\/10.3389\/fphar.2022.835510. PMID: 35517794; PMCID: PMC9062035.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1403_CR80","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/ehf2.14360","volume":"10","author":"VA Rossi","year":"2023","unstructured":"Rossi VA, Gawinecka J, Dimitriou F, von Eckardstein A, Dummer R, Ruschitzka F, et al. Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis: rechallenge? ESC Heart Fail. 2023;10(4):2680\u20135. https:\/\/doi.org\/10.1002\/ehf2.14360.","journal-title":"ESC Heart Fail"},{"key":"1403_CR81","doi-asserted-by":"publisher","unstructured":"Ang E, Mweempwa A, Heron C, Ahn Y, Rivalland G, Ha LY, Deva S. Cardiac Troponin I and T in Checkpoint Inhibitor-associated Myositis and Myocarditis. J Immunother. 2021;44(4):162\u2013163. https:\/\/doi.org\/10.1097\/CJI.0000000000000356. PMID: 33416262.","DOI":"10.1097\/CJI.0000000000000356"},{"issue":"5","key":"1403_CR82","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jaccao.2024.07.001","volume":"6","author":"A Barac","year":"2024","unstructured":"Barac A, Wadlow RC, Deeken JF, deFilippi C. Cardiac Troponin I and T in ICI Myocarditis Screening, Diagnosis, and Prognosis. JACC CardioOncol. 2024;6(5):804\u20137. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.001. PMID: 39479330; PMCID: PMC11520212.","journal-title":"JACC CardioOncol"},{"key":"1403_CR83","doi-asserted-by":"publisher","first-page":"115186","DOI":"10.1016\/j.ejca.2024.115186","volume":"216","author":"D Tomsitz","year":"2025","unstructured":"Tomsitz D, Grabmaier U, Spiro J, Nicolai L, French LE, Massberg S, Heinzerling L. Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T. Eur J Cancer. 2025;216:115186. https:\/\/doi.org\/10.1016\/j.ejca.2024.115186. Epub 2024 Dec 15. PMID: 39708617.","journal-title":"Eur J Cancer"},{"key":"1403_CR84","doi-asserted-by":"publisher","unstructured":"Herrmann J, Barac A, Carver J, Cheng RK, Daniele A, Dent S, Deych E, Lee DH, Lenihan D, Leong DP, Liu J, Lopez-Fernandez T, Lyon AR, Fradley M, Macedo AVS, Mooradian MJ, Nohria A, Porter C, Rassaf T, Suero-Abreu G, Sverdlov AL, Thavendiranathan P, Neilan TG, Mitchell JD. Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement. JAMA Oncol. 2025 Nov;13. https:\/\/doi.org\/10.1001\/jamaoncol.2025.4543. Epub ahead of print. PMID: 41231466.","DOI":"10.1001\/jamaoncol.2025.4543"},{"issue":"6","key":"1403_CR85","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jaccao.2025.06.009","volume":"7","author":"E Cheng","year":"2025","unstructured":"Cheng E, Ivanovic M, Chan A, Xu S, Franquiz M, Lee C, et al. Cardiac troponin screening and clinical outcomes in patients receiving immunotherapy. JACC CardioOncol. 2025;7(6):708\u201321. https:\/\/doi.org\/10.1016\/j.jaccao.2025.06.009.","journal-title":"JACC CardioOncol"},{"issue":"24","key":"1403_CR86","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.3390\/jcm12247737","volume":"12","author":"F Frascaro","year":"2023","unstructured":"Frascaro F, Bianchi N, Sanguettoli F, Marchini F, Meossi S, Zanarelli L, Tonet E, Serenelli M, Guardigli G, Campo G, Calabr\u00f2 L, Pavasini R. Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge. J Clin Med. 2023;12(24):7737. https:\/\/doi.org\/10.3390\/jcm12247737. PMID: 38137806; PMCID: PMC10744238.","journal-title":"J Clin Med"},{"key":"1403_CR87","doi-asserted-by":"publisher","first-page":"1455347","DOI":"10.3389\/fimmu.2025.1455347","volume":"16","author":"X Man","year":"2025","unstructured":"Man X, Wang H, Chen C, Cong X, Sun L, Sun X, Chen C, Zhang J, Yang L. Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review. Front Immunol. 2025;16:1455347. https:\/\/doi.org\/10.3389\/fimmu.2025.1455347. PMID: 40013153; PMCID: PMC11860070.","journal-title":"Front Immunol"},{"key":"1403_CR88","doi-asserted-by":"publisher","first-page":"884776","DOI":"10.3389\/fphar.2022.884776","volume":"13","author":"Y Nakagomi","year":"2022","unstructured":"Nakagomi Y, Tajiri K, Shimada S, Li S, Inoue K, Murakata Y, Murata M, Sakai S, Sato K, Ieda M. Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature. Front Pharmacol. 2022;13:884776. PMID: 35645839; PMCID: PMC9135130.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1403_CR89","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3390\/life13071518","volume":"13","author":"R R\u00edos-Tamayo","year":"2023","unstructured":"R\u00edos-Tamayo R, Krsnik I, G\u00f3mez-Bueno M, Garcia-Pavia P, Segovia-Cubero J, Huerta A, Salas C, Silvestre R\u00c1, S\u00e1nchez A, Manso M, Delgado L, Lahuerta JJ, Mart\u00ednez-L\u00f3pez J, Duarte RF. AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor. Life (Basel). 2023;13(7):1518. https:\/\/doi.org\/10.3390\/life13071518. PMID: 37511893; PMCID: PMC10382070.","journal-title":"Life (Basel)"},{"issue":"5","key":"1403_CR90","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1002\/ehf2.14852","volume":"11","author":"G Neculae","year":"2024","unstructured":"Neculae G, Adam R, Jercan A, B\u0103deli\u021b\u0103 S, Tjahjadi C, Draghici M, et al. Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms. ESC Heart Fail. 2024;11(5):2825\u201334. https:\/\/doi.org\/10.1002\/ehf2.14852.","journal-title":"ESC Heart Fail"},{"key":"1403_CR91","doi-asserted-by":"publisher","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):e7-e22. doi: 10.1161\/CIR.0000000000000792. Epub 2020 Jun 1. Erratum in: Circulation. 2021;144(1):e10. doi: 10.1161\/CIR.0000000000000997. Erratum in: Circulation. 2021;144(1):e11. https:\/\/doi.org\/10.1161\/CIR.0000000000000998. PMID: 32476490.","DOI":"10.1161\/CIR.0000000000000998"},{"issue":"3","key":"1403_CR92","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10741-025-10493-3","volume":"30","author":"A Aimo","year":"2025","unstructured":"Aimo A, Ferrari Chen YF, Castiglione V, Passino C, Genovesi D, Giorgetti A, Emdin M, Vergaro G. Positron emission tomography in cardiac amyloidosis: current evidence and future directions. Heart Fail Rev. 2025;30(3):605\u201318. https:\/\/doi.org\/10.1007\/s10741-025-10493-3. Epub 2025 Feb 10. PMID: 39924609; PMCID: PMC11991988.","journal-title":"Heart Fail Rev"},{"key":"1403_CR93","doi-asserted-by":"publisher","unstructured":"Herrera-Flores J, Vernooij RWM, Ghosh AK, Wechalekar A, Cheng RK, Keramida K, Anguita M, Sanchez PL, Del Perez C, Herrera-Flores C. Prognostic value of right ventricular longitudinal strain assessed by multimodal imaging in amyloidosis: systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging. 2025;26(10):1644\u20131661. https:\/\/doi.org\/10.1093\/ehjci\/jeaf216. PMID: 40795094.","DOI":"10.1093\/ehjci\/jeaf216"},{"issue":"1","key":"1403_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102883","volume":"50","author":"A Albulushi","year":"2025","unstructured":"Albulushi A, Buraiki JA, Aly G, Al-Wahshi Y, Jahangirifard A. Role of biomarkers in early diagnosis and prognosis of cardiac amyloidosis: a systematic review and meta-analysis. Curr Probl Cardiol. 2025;50(1):102883. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102883.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"1403_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2023.12.006","volume":"6","author":"L De Michieli","year":"2024","unstructured":"De Michieli L, Cipriani A, Iliceto S, Dispenzieri A, Jaffe AS. Cardiac Troponin in Patients With Light Chain and Transthyretin Cardiac Amyloidosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2024;6(1):1\u201315. PMID: 38510286; PMCID: PMC10950441.","journal-title":"JACC CardioOncol"},{"issue":"2","key":"1403_CR96","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/ejhf.2113","volume":"23","author":"V Castiglione","year":"2021","unstructured":"Castiglione V, Franzini M, Aimo A, Carecci A, Lombardi CM, Passino C, et al. Use of biomarkers to diagnose and manage cardiac amyloidosis. Eur J Heart Fail. 2021;23(2):217\u201330. https:\/\/doi.org\/10.1002\/ejhf.2113.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"1403_CR97","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ejhf.2769","volume":"25","author":"G Vergaro","year":"2023","unstructured":"Vergaro G, Castiglione V, Aimo A, Prontera C, Masotti S, Musetti V, et al. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis. Eur J Heart Fail. 2023;25(3):335\u201346. https:\/\/doi.org\/10.1002\/ejhf.2769.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"1403_CR98","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.125.012816","volume":"18","author":"L De Michieli","year":"2025","unstructured":"De Michieli L, Sinigiani G, Guida G, Saturi G, Sena G, Capovilla TM, et al. High-sensitivity cardiac troponin I for risk stratification in wild-type transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2025;18(8):e012816. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.125.012816.","journal-title":"Circ Heart Fail"},{"key":"1403_CR99","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","volume":"161","author":"CS Marnell","year":"2021","unstructured":"Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J Mol Cell Cardiol. 2021;161:98\u2013105. https:\/\/doi.org\/10.1016\/j.yjmcc.2021.07.004.","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"1403_CR100","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11912-023-01382-9","volume":"25","author":"I Singh","year":"2023","unstructured":"Singh I, Singh A. Clonal hematopoiesis of indeterminate potential: current understanding and future directions. Curr Oncol Rep. 2023;25(6):539\u201347. https:\/\/doi.org\/10.1007\/s11912-023-01382-9.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"1403_CR101","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","volume":"17","author":"S Jaiswal","year":"2020","unstructured":"Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat Rev Cardiol. 2020;17(3):137\u201344. https:\/\/doi.org\/10.1038\/s41569-019-0247-5.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"1403_CR102","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.120.318575","volume":"128","author":"MA Evans","year":"2021","unstructured":"Evans MA, Walsh K. A single-cell analysis of DNMT3A-mediated clonal hematopoiesis in heart failure. Circ Res. 2021;128(2):229\u201331. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.318575.","journal-title":"Circ Res"},{"issue":"5","key":"1403_CR103","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","volume":"7","author":"EC Svensson","year":"2022","unstructured":"Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, Xu H, D\u2019Aco K, Fernandez A, Wache-Mainier C, Libby P, Ridker PM, Beste MT, Basson CT. TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial. JAMA Cardiol. 2022;7(5):521\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2022.0386. PMID: 35385050; PMCID: PMC8988022.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"1403_CR104","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3390\/life13091801","volume":"13","author":"M Kislikova","year":"2023","unstructured":"Kislikova M, Lopez MAB, Salinas FJF, Blanco JAP, Molina MPG, Fernandez AA, Haces VCP, Unzueta MTG, Hern\u00e1ndez AB, Millan JCRS, Rodrigo Calabia E. Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology. Life (Basel). 2023;13(9):1801. https:\/\/doi.org\/10.3390\/life13091801. PMID: 37763205; PMCID: PMC10532913.","journal-title":"Life (Basel)"},{"issue":"10","key":"1403_CR105","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/ejhf.3408","volume":"26","author":"FL Scolari","year":"2024","unstructured":"Scolari FL, Brahmbhatt D, Abelson S, Lee D, Kim RH, Pedarzadeh A, Sakhnini A, Adler A, Chan RH, Dick JE, Rakowski H, Billia F. Clonal haematopoiesis is associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy. Eur J Heart Fail. 2024;26(10):2193\u2013202. https:\/\/doi.org\/10.1002\/ejhf.3408. Epub 2024 Aug 1. PMID: 39091134.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"1403_CR106","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1055\/s-0043-1770149","volume":"58","author":"A Guedes","year":"2023","unstructured":"Guedes A, Becker RG, Teixeira LEM. Multiple Myeloma (Part 1) - Update on Epidemiology, Diagnostic Criteria, Systemic Treatment and Prognosis. Rev Bras Ortop (Sao Paulo). 2023;58(3):361\u20137. https:\/\/doi.org\/10.1055\/s-0043-1770149. PMID: 37396092; PMCID: PMC10310414.","journal-title":"Rev Bras Ortop (Sao Paulo)"},{"key":"1403_CR107","doi-asserted-by":"publisher","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN. Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022;327(5):464\u2013477. https:\/\/doi.org\/10.1001\/jama.2022.0003. PMID: 35103762.","DOI":"10.1001\/jama.2022.0003"},{"key":"1403_CR108","doi-asserted-by":"publisher","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u2013427. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5. PMID: 33516340.","DOI":"10.1016\/S0140-6736(21)00135-5"},{"issue":"1","key":"1403_CR109","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","volume":"13","author":"J El-Cheikh","year":"2023","unstructured":"El-Cheikh J, Moukalled N, Malard F, Bazarbachi A, Mohty M. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies. Blood Cancer J. 2023;13(1):83. https:\/\/doi.org\/10.1038\/s41408-023-00849-z. PMID: 37208317; PMCID: PMC10199017.","journal-title":"Blood Cancer J"},{"issue":"2","key":"1403_CR110","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/bcp.15499","volume":"89","author":"Z Al-Yafeai","year":"2023","unstructured":"Al-Yafeai Z, Ghoweba M, Ananthaneni A, Abduljabar H, Aziz D. Cardiovascular complications of modern multiple myeloma therapy: a pharmacovigilance study. Br J Clin Pharmacol. 2023;89(2):641\u20138. https:\/\/doi.org\/10.1111\/bcp.15499.","journal-title":"Br J Clin Pharmacol"},{"key":"1403_CR111","doi-asserted-by":"publisher","first-page":"994384","DOI":"10.3389\/fcvm.2022.994384","volume":"9","author":"J Wang","year":"2022","unstructured":"Wang J, Yang S, Liao P, Zeng L, Ling W, Wan L, Weng J, Zhong L. Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma. Front Cardiovasc Med. 2022;9:994384. PMID: 36119749; PMCID: PMC9479066.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"1403_CR112","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/biom14020199","volume":"14","author":"U Attanasio","year":"2024","unstructured":"Attanasio U, Di Sarro E, Tricarico L, Di Lisi D, Armentaro G, Miceli S, Fioretti F, Deidda M, Correale M, Novo G, Sciacqua A, Nodari S, Cadeddu C, Tocchetti CG, Palazzuoli A, Mercurio V. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond. Biomolecules. 2024;14(2):199. https:\/\/doi.org\/10.3390\/biom14020199. PMID: 38397436; PMCID: PMC10887095.","journal-title":"Biomolecules"},{"issue":"1","key":"1403_CR113","doi-asserted-by":"publisher","first-page":"e34186","DOI":"10.7759\/cureus.34186","volume":"15","author":"O Bajwa","year":"2023","unstructured":"Bajwa O, Hassen G, Fishbein J, Uchenna U, Ammar H. False Elevation of Troponin in a Case of Multiple Myeloma. Cureus. 2023;15(1):e34186. https:\/\/doi.org\/10.7759\/cureus.34186. PMID: 36843687; PMCID: PMC9951548.","journal-title":"Cureus"},{"issue":"9","key":"1403_CR114","doi-asserted-by":"publisher","first-page":"ytac353","DOI":"10.1093\/ehjcr\/ytac353","volume":"6","author":"FJ Ruperti-Repilado","year":"2022","unstructured":"Ruperti-Repilado FJ, van der Stouwe JG, Haaf P, Mueller C, L\u00e4ubli H, Pfister O, Rothschild SI, Kuster GM. Case report of elevation of high-sensitivity cardiac troponin T in the absence of cardiac involvement in immune checkpoint inhibitor-associated myositis. Eur Heart J Case Rep. 2022;6(9):ytac353. https:\/\/doi.org\/10.1093\/ehjcr\/ytac353. PMID: 36090458; PMCID: PMC9449681.","journal-title":"Eur Heart J Case Rep"},{"issue":"1","key":"1403_CR115","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12872-024-04141-1","volume":"24","author":"M Nanyoshi","year":"2024","unstructured":"Nanyoshi M, Hayashi T, Sugimoto R, Nishisaki H, Kenzaka T. Type I Kounis syndrome in a young woman without chest pain: a case report. BMC Cardiovasc Disord. 2024;24(1):467. https:\/\/doi.org\/10.1186\/s12872-024-04141-1. PMID: 39218904; PMCID: PMC11367997.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"1403_CR116","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12872-023-03289-6","volume":"23","author":"Y Deng","year":"2023","unstructured":"Deng Y, Peng Z, Peng X. Type I Kounis syndrome induced by COVID-19 vaccination in China: a case report. BMC Cardiovasc Disord. 2023;23(1):267. https:\/\/doi.org\/10.1186\/s12872-023-03289-6. PMID: 37221464; PMCID: PMC10203661.","journal-title":"BMC Cardiovasc Disord"},{"key":"1403_CR117","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.2147\/IJGM.S536154","volume":"18","author":"V Dogan","year":"2025","unstructured":"Dogan V, Celik O, Demirci E, Calapkorur B. Clinical Features, Course and Prognosis of Kounis Syndrome. Int J Gen Med. 2025;18:6543\u201350. https:\/\/doi.org\/10.2147\/IJGM.S536154. PMID: 41185781; PMCID: PMC12579830.","journal-title":"Int J Gen Med"},{"issue":"6","key":"1403_CR118","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3390\/jcm13061647","volume":"13","author":"R Brancaccio","year":"2024","unstructured":"Brancaccio R, Bonzano L, Cocconcelli A, Boyko R, Ienopoli G, Motolese A. Recurrent Kounis Syndrome: A Case Report and Literature Review. J Clin Med. 2024;13(6):1647. https:\/\/doi.org\/10.3390\/jcm13061647. PMID: 38541873; PMCID: PMC10970901.","journal-title":"J Clin Med"},{"issue":"3","key":"1403_CR119","doi-asserted-by":"publisher","first-page":"365","DOI":"10.21873\/cdp.10225","volume":"3","author":"V Cirnigliaro","year":"2023","unstructured":"Cirnigliaro V, Pietrosanti S, Demofonti C, DE Angeli M, Giovenco D, Cedrone L, Sciommari C, Carosi A, Pietrasanta F, Ramella S, D\u2019Angelillo RM. V5 and High Sensitivity Cardiac Troponin T for Early Detection of Cardiac Toxicity During Left Breast Cancer Irradiation. Cancer Diagn Progn. 2023;3(3):365\u20139. https:\/\/doi.org\/10.21873\/cdp.10225. PMID: 37168962; PMCID: PMC10165385.","journal-title":"Cancer Diagn Progn"},{"issue":"10","key":"1403_CR120","doi-asserted-by":"publisher","first-page":"9049","DOI":"10.3390\/curroncol30100654","volume":"30","author":"K Antunac","year":"2023","unstructured":"Antunac K, Mayer L, Banovic M, Beketic-Oreskovic L. Correlation of High-Sensitivity Cardiac Troponin I Values and Cardiac Radiation Doses in Patients with Left-Sided Breast Cancer Undergoing Hypofractionated Adjuvant Radiotherapy with Concurrent Anti-HER2 Therapy. Curr Oncol. 2023;30(10):9049\u201362. https:\/\/doi.org\/10.3390\/curroncol30100654. PMID: 37887554; PMCID: PMC10605836.","journal-title":"Curr Oncol"},{"key":"1403_CR121","doi-asserted-by":"publisher","unstructured":"Yager K, Fan J, Sanford CB, Pourfarrokh N, Nguyen V. Among the Masses: Multiple Left Atrial Undifferentiated Pleomorphic Sarcomas. Ochsner J. 2024 Winter;24(4):279\u201383. https:\/\/doi.org\/10.31486\/toj.23.0143. PMID: 39720829; PMCID: PMC11666110.","DOI":"10.31486\/toj.23.0143"},{"key":"1403_CR122","doi-asserted-by":"publisher","first-page":"175883591878014","DOI":"10.1177\/1758835918780140","volume":"10","author":"JD Sara","year":"2018","unstructured":"Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, Herrmann J, Lerman A, Grothey A. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140. PMID: 29977352; PMCID: PMC6024329.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"1403_CR123","doi-asserted-by":"publisher","first-page":"e0265767","DOI":"10.1371\/journal.pone.0265767","volume":"17","author":"A Zafar","year":"2022","unstructured":"Zafar A, Drobni ZD, Lei M, Gongora CA, Quinaglia T, Lou UY, Mosarla R, Murphy SP, Jones-O\u2019Connor M, Mahmood A, Hartmann S, Gilman HK, Weekes CD, Nipp R, Clark JR, Clark JW, Blaszkowsky LS, Tavares E, Neilan TG. The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. PLoS ONE. 2022;17(4):e0265767. https:\/\/doi.org\/10.1371\/journal.pone.0265767. PMID: 35390017; PMCID: PMC8989300.","journal-title":"PLoS ONE"},{"issue":"5","key":"1403_CR124","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3390\/jcm11051244","volume":"11","author":"N Fabin","year":"2022","unstructured":"Fabin N, Bergami M, Cenko E, Bugiardini R, Manfrini O. The Role of Vasospasm and Microcirculatory Dysfunction in Fluoropyrimidine-Induced Ischemic Heart Disease. J Clin Med. 2022;11(5):1244. https:\/\/doi.org\/10.3390\/jcm11051244. PMID: 35268333; PMCID: PMC8910913.","journal-title":"J Clin Med"},{"issue":"8","key":"1403_CR125","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.3390\/curroncol31080357","volume":"31","author":"A Cio\u0142ek","year":"2024","unstructured":"Cio\u0142ek A, Piotrowski G. Comparison of Diagnostic Parameters of Acute Coronary Syndromes in Patients with and without Cancer: A Multifactorial Analysis. Curr Oncol. 2024;31(8):4769\u201380. https:\/\/doi.org\/10.3390\/curroncol31080357. PMID: 39195340; PMCID: PMC11352875.","journal-title":"Curr Oncol"},{"issue":"5","key":"1403_CR126","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jaccao.2023.08.001","volume":"5","author":"P Bima","year":"2023","unstructured":"Bima P, Lopez-Ayala P, Koechlin L, Boeddinghaus J, Nestelberger T, Okamura B, Muench-Gerber TS, Sanzone A, Skolozubova D, Djurdjevic D, Rubini Gimenez M, Wildi K, Miro O, Mart\u00ednez-Nadal G, Martin-Sanchez FJ, Christ M, Keller D, Lindahl B, Giannitsis E, Mueller C. APACE and TRAPID-AMI Investigators. Chest Pain in Cancer Patients: Prevalence of Myocardial Infarction and Performance of High-Sensitivity Cardiac Troponins. JACC CardioOncol. 2023;5(5):591\u2013609. PMID: 37969646; PMCID: PMC10635894.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"1403_CR127","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40959-025-00320-x","volume":"11","author":"M Sabat\u00e9-Tormos","year":"2025","unstructured":"Sabat\u00e9-Tormos M, Bardaj\u00ed A, Peir\u00f3 OM, Carrasquer A, Cediel G, Ferreiro JL. Cancer and myocardial injury in patients with suspected acute coronary syndrome. Cardiooncology. 2025;11(1):21. https:\/\/doi.org\/10.1186\/s40959-025-00320-x. PMID: 39987454; PMCID: PMC11846249.","journal-title":"Cardiooncology"},{"issue":"4","key":"1403_CR128","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3390\/jcm12041612","volume":"12","author":"C Mauro","year":"2023","unstructured":"Mauro C, Capone V, Cocchia R, Cademartiri F, Riccardi F, Arcopinto M, Alshahid M, Anwar K, Carafa M, Carbone A, Castaldo R, Chianese S, Crisci G, D\u2019Assante R, De Luca M, Franzese M, Galzerano D, Maffei V, Marra AM, Mazza A, Ranieri B, D\u2019Agostino A, Rega S, Romano L, Scagliarini S, Sepe C, Vriz O, Izzo R, Cittadini A, Bossone E, Salzano A. Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments: Definition, Classification, and Diagnostic Pathways. J Clin Med. 2023;12(4):1612. https:\/\/doi.org\/10.3390\/jcm12041612. PMID: 36836147; PMCID: PMC9962102.","journal-title":"J Clin Med"},{"issue":"6","key":"1403_CR129","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3892\/etm.2022.11679","volume":"24","author":"H Zhao","year":"2022","unstructured":"Zhao H, Liang F, Ling Y, Li T, Fang B, Deng T, Ying Y, He Y. Prevalence and treatment of venous thromboembolism in patients with solid tumors. Exp Ther Med. 2022;24(6):743. https:\/\/doi.org\/10.3892\/etm.2022.11679. PMID: 36478882; PMCID: PMC9716337.","journal-title":"Exp Ther Med"},{"issue":"3","key":"1403_CR130","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1055\/s-0044-1779672","volume":"50","author":"MB Betts","year":"2024","unstructured":"Betts MB, Liu X, Junqueira DR, Fahrbach K, Neupane B, Ronnebaum S, Dhamane AD. Risk of Venous Thromboembolism by Cancer Type: A Network Meta-Analysis. Semin Thromb Hemost. 2024;50(3):328\u201341. https:\/\/doi.org\/10.1055\/s-0044-1779672. Epub 2024 Feb 23. PMID: 38395064.","journal-title":"Semin Thromb Hemost"},{"key":"1403_CR131","doi-asserted-by":"publisher","first-page":"1405147","DOI":"10.3389\/fonc.2024.1405147","volume":"14","author":"Y Xu","year":"2024","unstructured":"Xu Y, Wu T, Ren X, Liu J, Zhang H, Yang D, Yan Y, Lv D. Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis. Front Oncol. 2024;14:1405147. PMID: 39206158; PMCID: PMC11350514.","journal-title":"Front Oncol"},{"issue":"15","key":"1403_CR132","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1182\/bloodadvances.2022009577","volume":"7","author":"MJT Crobach","year":"2023","unstructured":"Crobach MJT, Anijs RJS, Br\u00e6kkan SK, Severinsen MT, Hammerstr\u00f8m J, Skille H, Kristensen SR, Paulsen B, Tj\u00f8nneland A, Versteeg HH, Overvad K, Hansen JB, N\u00e6ss IA, Cannegieter SC. Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study. Blood Adv. 2023;7(15):4072\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2022009577. PMID: 37013958; PMCID: PMC10388725.","journal-title":"Blood Adv"},{"issue":"1","key":"1403_CR133","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40959-024-00281-7","volume":"10","author":"M Zaborowska-Szmit","year":"2024","unstructured":"Zaborowska-Szmit M, Szmit S, Olszyna-Serementa M, Zajda K, Janowicz-\u017bebrowska A, Ja\u015bkiewicz P, Kowalski DM, Krzakowski M. Venous thromboembolism is associated with increased all-cause mortality in ALK-positive non-small cell lung cancer. Cardiooncology. 2024;10(1):79. https:\/\/doi.org\/10.1186\/s40959-024-00281-7. PMID: 39522050; PMCID: PMC11549755.","journal-title":"Cardiooncology"},{"key":"1403_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2025.102764","volume":"95","author":"J Harry","year":"2025","unstructured":"Harry J, Bucciol R, Finnigan D, Hashem H, Araki A, Othman M. The incidence of venous thromboembolism by type of solid cancer worldwide: a systematic review. Cancer Epidemiol. 2025;95:102764. https:\/\/doi.org\/10.1016\/j.canep.2025.102764.","journal-title":"Cancer Epidemiol"},{"key":"1403_CR135","doi-asserted-by":"publisher","first-page":"1619554","DOI":"10.3389\/fonc.2025.1619554","volume":"15","author":"V Singh","year":"2025","unstructured":"Singh V, Tabassum H, Kohli S, Rulu P, Aggarwal S. Burden and distribution of venous thromboembolism across cancer types and stages: a meta-analysis of observational studies. Front Oncol. 2025;15:1619554. https:\/\/doi.org\/10.3389\/fonc.2025.1619554. PMID: 41098701; PMCID: PMC12518063.","journal-title":"Front Oncol"},{"issue":"1","key":"1403_CR136","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2390200","volume":"56","author":"R Yang","year":"2024","unstructured":"Yang R, Wang H, Liu D, Li W. Incidence and risk factors of VTE in lung cancer: a meta-analysis. Ann Med. 2024;56(1):2390200. https:\/\/doi.org\/10.1080\/07853890.2024.2390200.","journal-title":"Ann Med"},{"issue":"8","key":"1403_CR137","doi-asserted-by":"publisher","first-page":"e67922","DOI":"10.7759\/cureus.67922","volume":"16","author":"L Yang","year":"2024","unstructured":"Yang L, Li B, Chen H, Belfeki N, Monchi M, Moini C. The Role of Troponin in the Diagnosis and Treatment of Acute Pulmonary Embolism: Mechanisms of Elevation, Prognostic Evaluation, and Clinical Decision-Making. Cureus. 2024;16(8):e67922. https:\/\/doi.org\/10.7759\/cureus.67922. PMID: 39328637; PMCID: PMC11426936.","journal-title":"Cureus"},{"issue":"7","key":"1403_CR138","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1002\/ccd.70243","volume":"106","author":"AT Elmewafy","year":"2025","unstructured":"Elmewafy AT, Waller J, Alaguraja P, Desor K, Antoun I. The prognostic value of troponin in acute pulmonary embolism: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2025;106(7):3899\u2013916. https:\/\/doi.org\/10.1002\/ccd.70243.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"9","key":"1403_CR139","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3390\/medicina60091489","volume":"60","author":"AG Naum","year":"2024","unstructured":"Naum AG, Jari I, Moisii L, Ursu AM, Moisii P. Imaging and Biomarkers: The Assesment of Pulmonary Embolism Risk and Early Mortality. Med (Kaunas). 2024;60(9):1489. https:\/\/doi.org\/10.3390\/medicina60091489. PMID: 39336530; PMCID: PMC11433879.","journal-title":"Med (Kaunas)"},{"issue":"5","key":"1403_CR140","doi-asserted-by":"publisher","first-page":"oeae079","DOI":"10.1093\/ehjopen\/oeae079","volume":"4","author":"J Kauppi","year":"2024","unstructured":"Kauppi J, Airaksinen KEJ, Lehto J, Pouru JP, Saha J, Purola P, Jaakkola S, Lehtonen J, Vasankari T, Juonala M, Kiviniemi T. Performance of D-dimer, cardiac troponin T, C-reactive protein, and NT-proBNP in prediction of long-term mortality in patients with suspected pulmonary embolism. Eur Heart J Open. 2024;4(5):oeae079. https:\/\/doi.org\/10.1093\/ehjopen\/oeae079. PMID: 39399207; PMCID: PMC11467688.","journal-title":"Eur Heart J Open"},{"key":"1403_CR141","doi-asserted-by":"crossref","unstructured":"Ganatra S, Barac A, Armenian S, Cambareri C, Denlinger CS, Dent SF, Hayek S, Ky B, Leja M, Lucas CH, Makwana B, Palaskas NL, Vo JB. Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton\u2019s Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2025 Dec 10:S0735-1097(25)09916-4. doi: 10.1016\/j.jacc.2025.10.018. Epub ahead of print. PMID: 41369617.","DOI":"10.1016\/j.jacc.2025.10.018"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01403-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01403-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01403-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:03:17Z","timestamp":1784581397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01403-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1403"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01403-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"38"}}